What is Euroapi S.A?
develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally.
EAPIF · Verdict
Moderate reward · moderate risk
EAPIF stands out on volatility and balance sheet, but watch the profitability signal.
Based on 88% data coverage
EAPIF · Verdict
Top decile vs peers
Current ratio 2.53
-14% net margin · -13% ROE
Rev +1.0% CAGR · earnings +152.6%
Model-based scoring. For information only — not financial advice.
develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 264.06M.
The scoring profile indicates limited reward potential at this time, with momentum and size offering the most support. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.